Cargando…
M84. METFORMIN FOR EARLY CO-MORBID PREDIABETES OR DIABETES IN SCHIZOPHRENIA SPECTRUM DISORDERS: A DOUBLE BLIND RANDOMIZED PILOT STUDY
BACKGROUND: Patients with severe mental illness (SMI) loose 15–20 years of life due to cardiovascular disease. Much of the metabolic risk, including high rates of type 2 diabetes (T2D) is accrued early on in the illness, highlighting the need for early intervention strategies to target modifiable ca...
Autores principales: | Mahavir Agarwal, Sri, Panda, Roshni, Costa-Dookhan, Kenya, Mackenzie, Nicole, Casuccio-Treen, Quinn, Caravaggio, Fernando, Eyesha, Hashim, Kirpalani, Anish, Chintoh, Araba, Voineskos, Aristotle, Kramer, Caroline, Graff-Guerrero, Ariel, Remington, Gary, Hahn, Margaret |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234539/ http://dx.doi.org/10.1093/schbul/sbaa030.396 |
Ejemplares similares
-
Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial
por: Agarwal, Sri Mahavir, et al.
Publicado: (2021) -
S89. INVESTIGATING METABOLIC DYSFUNCTION AND METABOLOMIC PROFILE CHANGES IN ANTIPSYCHOTIC NAIVE PATIENTS
por: Costa-Dookhan, Kenya, et al.
Publicado: (2020) -
Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018) -
T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020) -
Metabolomic signatures associated with weight gain and psychosis spectrum diagnoses: A pilot study
por: Lee, Jiwon, et al.
Publicado: (2023)